Theriva biologics announces positive recommendation from the independent data monitoring committee of virage, the phase 2b clinical trial of vcn-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma

The independent data monitoring committee (idmc) recommended the continuation of virage with no safety concerns raised; virage remains on track to complete enrollment in the first half of 2024 the independent data monitoring committee (idmc) recommended the continuation of virage with no safety concerns raised; virage remains on track to complete enrollment in the first half of 2024
TOVX Ratings Summary
TOVX Quant Ranking